Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US10544225B2 · kind B2 · utility
15Cited by
60References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2015 |
| Grant date | Jan 28, 2020 |
| Priority date | — |
| Expiry date | Sep 24, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.